Almac Group, the global contract development and manufacturing organisation, wishes to congratulate its long term client partner Wellstat Therapeutics on the commercial approval of their first orphan drug product XURIDEN™ (uridine triacetate). XURIDEN has been developed as a treatment for the rare disease Hereditary Orotic Aciduria (HOA).
Due to the overwhelming success experienced since the launch of its “Direct to Patient” shipping service for clinical trials throughout US and Canada in October last year, Almac has announced the expansion of this innovative service to EU countries.
Almac Discovery, a biopharmaceutical company focused on identifying and developing innovative therapeutics for the treatment of cancer, today announced a Research and Licensing agreement with Genentech, a member of the Roche Group (SIX:RO, ROG; OTCQX: RHHBY) to discover and develop small molecule inhibitors of a ubiquitin specific protease (USP) target.
Almac Group was last night named the winner of ‘The UKTI Award for Innovation’ in the final of this year’s European Business Awards, sponsored by RSM, at an exclusive awards ceremony held in London attended by prominent businesses leaders, European ambassadors and political representatives from the EU.The win celebrates the end of a yearlong journey for Almac that began in spring 2014 when the European Business Awards engaged with over 24,000 businesses at the entry stage of the competition. After being named one of 709 National Champions from 33 countries in November, the company took part in the public vote, which generated 174,000 votes, a record-breaking year.
Almac Group, the global contract development and manufacturing organisation, today announced the relocation of their peptide custom synthesis operations from their existing Elvingston facility to a custom designed, 7,000ft2 wing of the Fleming Building at the vibrant Edinburgh Technopole.
If you're in the pharmaceutical industry the cost of your floor space is much greater than it would be for some of the other industries we serve. A special interest to you would be our compact single place to blender that takes 25-75% less floor space than a traditional double pedestal blender or other types of IBC Blenders.
Within just two years of reaching a milestone of 2,500 employees, SHL Group has rapidly reached 3,000 employees worldwide. This increase is reflective of a steady yet rapid growth in the injectable drug delivery market and SHL’s effective commitment, productivity and management.
Novo Nordisk Pharmatech A/S is a leading global supplier of high-quality ingredients for the biopharmaceutical and pharmaceutical industries. The company has attracted an extensive roster of leading pharmaceutical companies through unsurpassed product quality, manufacturing and quality control, regulatory documentation, precision delivery and a comprehensive risk mitigation strategy.
JRS Pharma, producer of world-leading cellulose products for the health science industry, adds Celonic to its portfolio of products and services.
JRS Pharma, leading manufacturer of high functionality excipients, stabilizers, and nutritional and functional fibers for veterinary medicine and animal health supplements, offers innovative solutions for the global animal health industry.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.